Related posts

Meta leads rallycash, credit and healthATD, IXJ, but BABA?
Investor Insights

This summary was created by AI, based on 10 opinions in the last 12 months.

Experts are divided in their opinions regarding AbbVie Inc. Some believe it is making smart moves by acquiring companies to fill the gap left by the patent expiration of its big drug, Humira. Others see it as a weaker company facing more competition. However, the company's strong brand value, excellent management team, and history of good capital allocation make it resilient to economic fluctuations. The stock has been a good performer in 2022, though weak recently with most of healthcare, and is seen as a good hold in an uncertain economy.

Consensus
Mixed
Valuation
Fair Value
COMMENT
AbbVie Inc.

In the past 2 months they bought Immurgen (they have an ovarian cancer treatment and oncology portfolio) and Cerevel (a clinical stage biotech to treat, for example, Parkinson's, epilepsy). These are smart moves. Why? Competition. CVS just announced it is adopting biosimilars (generic drugs), including removing Humira (Abbvie's big drug which came off patent).

0
SELL
AbbVie Inc.

Sold because Humera was coming off patent. A good move that avoided the opportunity cost of the stock just treading water. Trying to plug holes with acquisitions. Good company, but better opportunities elsewhere.

0
SELL
AbbVie Inc.

He sold Abbvie. He likes pharma, but this is a weaker name that's facing more competition.

0
TOP PICK
AbbVie Inc.

One of largest pharmacy companies in sector. Recently announced M&A plans for cancer drugs. Very strong brand value with excellent management team. Company very resilient to gyrations in economy. Price target is ~$160. Strong history of good capital allocation. Consistent dividend increases over past 50 years. Current dividend yield very safe. 

0
COMMENT
AbbVie Inc.

They're trying to fill the Humira whole which is going off patent, though is a huge-selling drug. They have to migrate people to use new drugs, and he thinks they can. He'd like to hear managers talk about this.

0
BUY
AbbVie Inc.

Great cash flow yield. A great performer in 2022, but has been recently weak with most of healthcare. Beyond healthcare, healthcare has the highest free cash flow, good to hold as we enter an uncertain economy.

0
premium

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Premium members

Discover an exclusive list and analysis of the stocks that are trending on social medias—accessible only to our Premium subscribers. With a keen focus on the stocks that are setting social media ablaze, this weekly feature offers an invaluable lens through which to evaluate market movers. Say goodbye to the endless scroll through social media timelines; we curate the buzz so you can invest your time as wisely as your money. Unlock Premium Now.

TOP PICK
AbbVie Inc.

AbbVie Inc. is a pharmaceutical company headquartered in North Chicago, Illinois. It is ranked 6th on the list of largest biomedical companies by revenue. Their primary product is Humira (adalimumab) ($21 billion in 2022 revenues, 37% of total), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohns disease, plaque psoriasis, and ulcerative colitis. Social media mentions are up 333% in the past 24h.

0
BUY
AbbVie Inc.

Has earnings power, margins and growth. People got too bearish on Humira's biosimilars. Skyrizi did much better than expected. Has strong free cash flow. A good way to diversify away from tech.

0
BUY
AbbVie Inc.
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

EPS of $2.91 beat estimates of $2.87 and revenues of $13.87B beat estimates of $13.51B. Revenues declined by 4.9%, and its adjusted diluted EPS declined 13.6%, which includes an unfavourable impact of $0.15 per share related to acquired IPR&D and milestones expense. Its immunology portfolio saw revenues decline 5.5%, which Humira net revenues declining 25.2%. Hematologic Oncology portfolio revenues decreased 10.4%, and its Neuroscience portfolio increased sales by 13.6%. Management raised 2023 adjusted diluted EPS guidance to $10.90 - $11.10 from $10.57 - $10.97. Its results, while witnessed a year-over-year decline, were above expectations, and driven by its non-Humira business, which delivered high single-digit sales growth. The raising of full-year guidance is encouraging, and it is progressing across all stages of its pipeline and benefiting from diversification amongst its portfolios. We would be comfortable buying ABBV at these levels, given its increased guidance and expectations for growth. 
Unlock Premium - Try 5i Free

0
BUY
AbbVie Inc.
ABBV vs. PFE

Prefers ABBV. Main overhang to PFE is what happens to the vaccine franchise now that we're on the other side of Covid? PFE will need other engines, it's a show-me story. ABBV is a leader in immunology. Humira is coming off patent, which will compress earnings, but that's well-known by the market. Its pipeline will fill the gap, plus Botox business.

0
DON'T BUY
AbbVie Inc.

Pays a 3.9% dividend, paying 14x forward earnings, but the EPS growth rate is likely under 5% annual forward. Problem is their big drug Humira comprises 43% of overall sales, but this patent expires this year--that's a problem. Abbvie does have a good pipeline though. Prefers Pfizer, Merck, etc.

0
BUY
AbbVie Inc.
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research.

 ABBV is set to see more competition on Humira, which is a multi-billion dollar product for it. But this is hardly new news. 
The issue has been discussed for years as the drug comes off patent. 
There hasn't been much material news; the company did say it was lifting its $2B cap on acquisitions, potentially worrying some investors who want debt to decline. 
The sector has also seen some weakness generally as investors move into other areas. It reports tomorrow and remains very cheap.  
We would not change a position.  
Unlock Premium - Try 5i Free

0
DON'T BUY
AbbVie Inc.

It reports Thursday. Recently, it's gotten negative press over the high-handed way ABBV protected the price of Humira, their big drug that has finally lost patent protection. Will it crush gross margins? Does management have enough to offset that loss? If management addresses this issue, shares could go down.

0
BUY
AbbVie Inc.
They have oncology and immunology drugs, and pay a solid dividend yield. A great toehold in healthcare.
0
BUY
AbbVie Inc.
Likes healthcare, entire sector sold off somewhat in January. Bit of an opportunity. 11x forward PE, pretty decent growth rate. Issues with expiring drug patents, but they'll replace these. One of the premier names in the space. He owns MRK and PFE. Nice yield of 3.9%.
0
Showing 1 to 15 of 148 entries

AbbVie Inc.(ABBV-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 5

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 4

Total Signals / Votes : 9

Stockchase rating for AbbVie Inc. is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

AbbVie Inc.(ABBV-N) Frequently Asked Questions

What is AbbVie Inc. stock symbol?

AbbVie Inc. is a American stock, trading under the symbol ABBV-N on the New York Stock Exchange (ABBV). It is usually referred to as NYSE:ABBV or ABBV-N

Is AbbVie Inc. a buy or a sell?

In the last year, 9 stock analysts published opinions about ABBV-N. 5 analysts recommended to BUY the stock. 4 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for AbbVie Inc..

Is AbbVie Inc. a good investment or a top pick?

AbbVie Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for AbbVie Inc..

Why is AbbVie Inc. stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is AbbVie Inc. worth watching?

9 stock analysts on Stockchase covered AbbVie Inc. In the last year. It is a trending stock that is worth watching.

What is AbbVie Inc. stock price?

On 2024-02-21, AbbVie Inc. (ABBV-N) stock closed at a price of $175.48.